GSK's investigational BCMA antibody-drug conjugate ...

GSK2857916, an anti-BCMA monoclonal antibody-drug conjugate, received PRIME and Breakthrough Therapy Designations for treating relapsed/refractory multiple myeloma. It also has orphan drug status from EMA and FDA. GSK plans to advance clinical trials, highlighting its potential to transform myeloma treatment.